Faculty Disclosures
| J. E. Ahlskog, MD, PhD |
Dr. Ahlskog has received publishing royalties from a publication relating to health care. |
| Steven T. DeKosky, MD, FAAN |
Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. DeKosky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail Pharamceuticls. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaccinex, Inc. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up-To-Date. Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics . |
| Charles S. DeCarli, MD, FAAN |
Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. DeCarli has received research support from NIH. |
| Carlos S. Kase, MD, FAHA, FAAN |
Dr. Kase has nothing to disclose. |
| Claudia Kawas, MD |
The institution of Dr. Kawas has received research support from NIH. |
| Jeffrey A. Kaye, MD, FAAN |
Dr. Kaye has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Kaye has stock in Life Analytics. The institution of Dr. Kaye has received research support from NIH. The institution of Dr. Kaye has received research support from NSF. The institution of Dr. Kaye has received research support from AbbVie. Dr. Kaye has received intellectual property interests from a discovery or technology relating to health care. |
| David S. Knopman, MD, FAAN |
Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH. |
| John C. Morris, MD, FAAN |
Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CBR International Advisory Board. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cure Alzheimers Fund. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LEADS Steering Commitee. The institution of Dr. Morris has received research support from NIH grants. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care. |
| Brian R. Ott, MD |
No disclosure on file
|
| Ronald C. Petersen, MD, PhD, FAAN |
Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities. |
| Philip A. Wolf, MD, FAAN |
No disclosure on file
|
| Oscar L. Lopez, MD, FAAN |
Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen. |
| Dennis W. Dickson, MD |
Dr. Dickson has nothing to disclose. |
| Bradley F. Boeve, MD, FAAN |
Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care. |
| James T. Becker, PhD |
No disclosure on file
|
| Howard J. Rosen, MD |
Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
| Sudha Seshadri, MD, FAAN |
Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Seshadri has received research support from NIH. The institution of Dr. Seshadri has received research support from Alzheimer Association. |
| Lisa Silbert, MD, FAAN |
The institution of Dr. Silbert has received research support from the NIH. Dr. Silbert has received personal compensation in the range of $0-$499 for serving as a Peer Reviewer, study section with NIH. |
| Maria Corrada, PhD |
The institution of Dr. Corrada has received research support from NIH. |
| Tanis J. Ferman, PhD |
Ms. Ferman has nothing to disclose. |
| Robert A. Sweet |
Robert A. Sweet has nothing to disclose. |
| Kirsten L. Gruis, MD |
No disclosure on file
|
| Carolyn F. Orr, MD |
No disclosure on file
|
| Aleksandra Pikula, MD |
The institution of Dr. Pikula has received research support from CIHR. |
|
No disclosure on file
|
| Rosebud O. Roberts, MD |
No disclosure on file
|
| Rhoda Au, PhD |
Dr. Au has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. Dr. Au has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Au has received publishing royalties from a publication relating to health care. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Davos Alzheimer's Collaborative. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with High Lantern. |
| Owen T. Carmichael, PhD |
No disclosure on file
|
| Eric M. McDade, DO |
Dr. McDade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. McDade has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alzamend. Dr. McDade has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fondation Alzheimer. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. The institution of Dr. McDade has received research support from NIA. The institution of Dr. McDade has received research support from Eli Lilly. The institution of Dr. McDade has received research support from Hoffman-La Roche. The institution of Dr. McDade has received research support from Eisai. The institution of Dr. McDade has received research support from Eisai. Dr. McDade has received intellectual property interests from a discovery or technology relating to health care. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board Member with Fondation Alzheimer. |
| Hiroko H. Dodge, PhD |
No disclosure on file
|
| Catherine M. Roe, PhD |
No disclosure on file
|
| Erica C. Camargo Faye, MD, PhD |
No disclosure on file
|
| Brendon P. Boot, MD, MBBS |
Dr. Boot has received personal compensation for serving as an employee of BlueRock Therapeutics. Dr. Boot has stock in Eyepoint Pharmaceuticals. |
| Carrie B. Peltz, PhD |
No disclosure on file
|
| Archana Balasubramanian |
No disclosure on file
|
| Halley Hindman |
No disclosure on file
|
| Jason J. Hassenstab |
No disclosure on file
|
| Rachel G. Pizzie |
No disclosure on file
|
| Rick Falzone |
No disclosure on file
|
| Akshay Vaishnaw |
Akshay Vaishnaw, 22867 has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Akshay Vaishnaw, 22867 has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Editas Medicine. Akshay Vaishnaw, 22867 has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Scholar Rock. Akshay Vaishnaw, 22867 has received stock or an ownership interest from Alnylam Pharmaceuticals. |
| Alexa Beiser |
Alexa Beiser has nothing to disclose. |